WASHINGTON — The Meals and Drug Administration can’t escape questions on Aduhelm.
Patrizia Cavazzoni, one of many company’s highest-ranking drug regulators, got down to testify earlier than Congress Thursday on the intricacies of three looming funding payments essential to the company’s operations. However repeatedly, lawmakers grilled her about Biogen’s controversial Alzhiemer’s drug.
